How to Use Interleukin-1 Antagonists in Patients With Pericarditis
Canadian Journal of Cardiology · 2023
DOI: 10.1016/j.cjca.2023.02.071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Cardiology, 2023. Verfasst von Ahmed Aldajani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine and Cardiovascular Imaging, McGill University Health Centre, Montreal, Quebec, Canada; Department of Internal M…. Hauptthemen laut MEDLINE: Interleukin-1, Pericarditis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Recurrent pericarditis (RP) is one of the most common complications of pericarditis, affecting 15-30% of patients after an initial episode and >40% after a first recurrence.[1, 2] Up to 5-10% of RP patients develop multiple recurrences that are difficult to treat and refractory to conventional anti-inflammatory therapy, suggestive of refractory corticosteroid-dependent, colchicine-resistant RP.[2, 3] Several treatment options are suggested for such patients, including interleukin-1 (IL-1) antagonists, which are currently off-label for treating pericarditis in Canada.[1, 3] This paper aims to provide a focused guide to using anti-IL-1 agents (specifically anakinra and rilonacept), including practical tips from our experience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine and Cardiovascular Imaging, McGill University Health Centre, Montreal, Quebec, Canada; Department of Internal Medicine, Division of Cardiology, College of Medicine, Imam Abdulrahman…
- Cardiology, Cardiothoracic Department, University Hospital Santa Maria della Misericordia, and University of Udine, Udine, Italy.
- Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: vartan.mardigyan@mail.mcgill.ca.
Zitieren
APA
Aldajani, A., Imazio, M., Klein, A., & Mardigyan, V. (2023). How to Use Interleukin-1 Antagonists in Patients With Pericarditis. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2023.02.071
Vancouver
Aldajani A, Imazio M, Klein A, Mardigyan V. How to Use Interleukin-1 Antagonists in Patients With Pericarditis. Canadian Journal of Cardiology. 2023. doi:10.1016/j.cjca.2023.02.071
BibTeX
@article{Aldajani2023,
author = {Aldajani, Ahmed and Imazio, Massimo and Klein, Allan and Mardigyan, Vartan},
title = {How to Use Interleukin-1 Antagonists in Patients With Pericarditis},
journal = {Canadian Journal of Cardiology},
year = {2023},
doi = {10.1016/j.cjca.2023.02.071}
}
EUVIMED